JAN - JanOne to acquire Soin Therapeutics

• JanOne ( NASDAQ: JAN ) has executed a term sheet to acquire Soin Therapeutics and its product, a patent-pending, novel formulation of low dose naltrexone.
• The product, that JanOne will name Jan123, is being developed for the treatment of Complex Regional Pain Syndrome, a severe, chronic pain generally affecting the arms or legs.
• The transaction has a value of $13M, with up to an additional $17M in value depending on the magnitude of the revenues ultimately generated by the Jan123 product, for a total value of up to $30M.
• Following completion of the transaction, JanOne will work to advance JAN123 through GMP manufacturing and into clinical trials.
• The Company anticipates filing an Investigational New Drug application in 2023 and beginning clinical development later in the year.

For further details see: